Rare severe pustular psoriasis family DNA study network
Treatments studied
Part of Skin clinical trials.
This study builds a large international registry of people with rare, severe pustular psoriasis to help doctors understand the genetics of the condition. You may be asked for information and, if you have eligible family members, DNA testing to learn how the disease runs in families.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal proxy) can give written consent to join the study registry
- A dermatologist has confirmed you have pustular psoriasis (a specific rare form)
- Your pustular psoriasis type can include palm/sole forms, nail-associated forms, or generalized forms
- In the past 6 months, you had visible pustules (small white/yellow/brown bumps), or you may still qualify even if it’s not active now
- You can read and understand the study information in the available language(s) so you can consent
- If you want, you can include certain adult family members (parents or siblings) for DNA trio testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a registry of people with generalized pustular psoriasis (a rare, severe skin condition with pus-filled blisters). The goal is to learn more about this condition and how it affects patients in Costa Rica. If you have a confirmed diagnosis, this registry may help researchers better understand GPP and improve future care.
This registry tracks the safety and effectiveness of GPP treatments in real-world settings. It helps doctors and researchers learn how well current and future medicines work for people with generalized pustular psoriasis.
This study tests an experimental drug called HB0034 for people with a sudden, severe flare of generalized pustular psoriasis (GPP). It aims to see if the drug can safely clear the pustules and improve symptoms.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This study uses nail information to build a diagnostic model for psoriasis and psoriatic arthritis. It may help improve diagnosis and treatment for these conditions.
Hear when a new Pustular Psoriasis (PP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.